文献速递产科母胎医学

基于母血血管生成生物标志物,足月子痫前期可分为临床特征与结局不同的2个聚类

Preeclampsia at term can be classified into 2 clusters with different clinical characteristics and outcomes based on angiogenic biomarkers in maternal blood.
PubMed 文献 · Am J Obstet Gynecol · 2022-11-03

本研究通过纵向巢式病例对照研究(子痫前期151例,对照540例)及病例系列(子痫前期452例),按分娩孕周分层分析血管生成/抗血管生成因子异常的发生率与临床意义。早产子痫前期几乎均存在异常血管生成谱,而足月子痫前期仅约50%存在此类异常;基于该谱可将足月子痫前期分为临床特征与母婴结局风险不同的2个聚类。

要点

  • 早产子痫前期异常血管生成谱比例高(病例对照研究早、中、足月分别为90%、100%、39%),足月约50%。
  • 足月异常谱组更多为初产妇(57% vs 35%)、较少吸烟(14% vs 26%),母体并发症(14% vs 5%)及新生儿并发症(7% vs 1%)风险更高。
  • 足月正常谱组更多合并慢性高血压(36% vs 21%)及肥胖≥2级(41% vs 23%)。

核心结论

  • 早产子痫前期几乎全部存在异常血管生成谱,而足月子痫前期仅约50%存在此类异常。
  • 基于血管生成生物标志物谱可将足月子痫前期按疾病机制分为2个聚类,其人口学特征、临床特征及不良母婴结局风险不同。

研究设计与样本

  • 研究包括两部分:(1)纵向巢式病例对照研究,子痫前期151例,对照组540例;(2)子痫前期病例系列452例。
  • 在子痫前期患者诊断时采集血液,采用酶联免疫吸附试验测定胎盘生长因子及可溶性fms样酪氨酸激酶-1的血浆浓度。
  • 异常血管生成谱定义为胎盘生长因子与可溶性fms样酪氨酸激酶-1血浆比值以中位数倍数表示低于基于纵向研究所得值的相应孕周第10百分位。

主要发现

  • 病例对照研究中异常血管生成谱发生率:早产(≤34周)90%、中间(34.1-36.9周)100%、足月(≥37周)39%;病例系列中分别为98%、80%、55%。
  • 足月子痫前期异常谱组较无异常谱组:初产妇57% vs 35%,吸烟14% vs 26%,母体并发症14% vs 5%,新生儿并发症7% vs 1%,符合母体血管灌注不良的胎盘病变42% vs 23%(均P<.05)。
  • 足月子痫前期正常谱组较异常谱组:慢性高血压36% vs 21%,肥胖≥2级41% vs 23%(均P<.05)。

关键数值与推荐

  • 异常血管生成谱定义为胎盘生长因子与可溶性fms样酪氨酸激酶-1血浆比值以中位数倍数表示低于相应孕周第10百分位。
  • 孕周分层:早产≤34周,中间34.1-36.9周,足月≥37周。

临床怎么用

  • 作者认为,这些发现为足月子痫前期提供了一种简单的分类方法,并对未来临床护理和研究有启示。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An antiangiogenic state has emerged as a mechanism of disease in preeclampsia. Angiogenic biomarkers are used in the risk assessment of this syndrome, particularly of early disease. The role of an antiangiogenic state in late preeclampsia is unclear. OBJECTIVE: This study aimed to determine the prevalence, characteristics, and clinical significance of angiogenic/antiangiogenic factor abnormalities in women with preeclampsia stratified according to gestational age at delivery. STUDY DESIGN: Two studies were conducted: (1) a longitudinal nested case-control study comprising women with preeclampsia (n=151) and a control group (n=540); and (2) a case series of patients with preeclampsia (n=452). In patients with preeclampsia, blood was collected at the time of diagnosis. Plasma concentrations of placental growth factor and soluble fms-like tyrosine kinase-1 were determined by enzyme-linked immunosorbent assays. An abnormal angiogenic profile was defined as a plasma ratio of placental growth factor and soluble fms-like tyrosine kinase-1 expressed as a multiple of the median <10th percentile for gestational age based on values derived from the longitudinal study. The proportion of patients diagnosed with preeclampsia who had an abnormal angiogenic profile was determined in the case-series participants and stratified by gestational age at delivery into early (≤34 weeks), intermediate (34.1-36.9 weeks), and term (≥37 weeks) preeclampsia. The demographics, clinical characteristics, and pregnancy outcomes of women with preeclampsia with and without an abnormal angiogenic profile were compared. RESULTS: The prevalence of an abnormal angiogenic profile was higher in preterm than in term preeclampsia (for early, intermediate, and term in the case-control study: 90%, 100%, and 39%; for the case series: 98%, 80%, and 55%, respectively). Women with preeclampsia at term who had an abnormal angiogenic profile were more frequently nulliparous (57% vs 35%), less likely to smoke (14% vs 26%), at greater risk for maternal (14% vs 5%) or neonatal (7% vs 1%) complications, and more often had placental lesions consistent with maternal vascular malperfusion (42% vs 23%; all, P<.05) than those without an abnormal profile. Women with preeclampsia at term who had a normal angiogenic profile had a higher frequency of chronic hypertension (36% vs 21%) and were more likely to have class ≥2 obesity (41% vs 23%) than those with an abnormal profile (both, P<.05). CONCLUSION: Patients with early preeclampsia had an abnormal angiogenic profile in virtually all cases, whereas only 50% of women with preeclampsia at term had such abnormalities. The profile of angiogenic biomarkers can be used to classify patients with preeclampsia at term, on the basis of mechanisms of disease, into 2 clusters, which have different demographics, clinical characteristics, and risks of adverse maternal and neonatal outcomes. These findings provide a simple approach to classify preeclampsia at term and have implications for future clinical care and research.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Chaiworapongsa T, Romero R, Gotsch F, et al. Preeclampsia at term can be classified into 2 clusters with different clinical characteristics and outcomes based on angiogenic biomarkers in maternal blood. Am J Obstet Gynecol. 2022. PMID: 36336082. doi:10.1016/j.ajog.2022.11.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。